Lotte Biologics completes construction of production plant in Incheon, eyes global expansion
Lotte Biologics completed construction of its biomanufacturing facility in Incheon, just west of Seoul, on Wednesday, marking a major step in its efforts to become a leading player in the global biopharmaceutical market. A completion ceremony for Plant 1, located at the company's Songdo Bio Campus in Incheon, was attended by the company's co-chief executive officers, James Park and Shin Yoo-yeol,…
Lotte Biologics has finished building its biomanufacturing plant in Incheon, Korea, signaling a significant step towards becoming a key player in the global biopharmaceutical industry. The Plant 1 facility, situated on the company's Songdo Bio Campus, was inaugurated in a ceremony that included the company's co-CEOs, James Park and Shin Yoo-yeol, as well as Lotte Group Chairman Shin Dong-bin.
Chairman Shin emphasized that biopharmaceuticals are Lotte Group's future growth engine and a pivotal industry for Korea's future. The 100,000 square meter plant boasts essential production facilities, such as a production building and wastewater treatment system, with an annual capacity of 120,000 liters. It is set to commence commercial operations in 2028, according to the company.
This facility will serve as a substantial production hub for Lotte Biologics within Korea, enhancing its manufacturing operations in Syracuse, New York, which were acquired in 2023.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.